High targeting specificity

After IV injection of Lunguide LNP-mRNA, the proportion of transfection in lung is up to 95%, and the risk of off-target in vivo is low.

High protein expression efficiency

Lunguide LNP-mRNA transfected lung cells quickly and the protein expression level is high. Lung cell transfection could be achieved within 10 min, and exhibited up to 200-fold higher bioluminescence intensity than of ALC-0315 LNP.

High safety profiles

The maximum tolerated dose of second-generation Lunguide LNP injected intravenously in mice was up to 6 mg/kg (nucleic acid dose) after IV injection.

Diverse payloads

Our Lunguide LNP can deliver diverse nucleic acids, including mRNA, siRNA, circRNA, and DNA, showcasing its potential in development of nucleic acid therapeutics.

High encapsulation rate and stability

The encapsulation rate of Lunguide LNP is higher than 95%, and it could be stably stored at 4℃ and -80℃.

Great application potential

Alveolar macrophages and capillary endothelial cells can be efficiently transfected after IV injection of Lunguide LNP-mRNA, showcasing its great potential in CAR-M cell therapy and lung cancer treatment.